Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 36, Issue 17, 2018, Pages 1714-1768

  Brahmer, Julie R ^a,b   Lacchetti, Christina ^c   Schneider, Bryan J ^e   Atkins, Michael B ^f   Brassil, Kelly J ^j   Caterino, Jeffrey M ^g   Chau, Ian ^l   Ernstoff, Marc S ^m   Gardner, Jennifer M ^a   Ginex, Pamela ^p   Hallmeyer, Sigrun ^q   Chakrabarty, Jennifer Holter ^r   Leighl, Natasha B ^t   Mammen, Jennifer S ^b,q   McDermott, David F ^u   Naing, Aung ^j   Nastoupil, Loretta J ^j   Phillips, Tanyanika ^s   Porter, Laura D ⁱ   Puzanov, Igor ^m   Reichner, Cristina A ^h   Santomasso, Bianca D ⁿ   Seigel, Carole ^q   Spira, Alexander ^d   Suarez Almazor, Maria E ^j   Wang, Yinghong ^j   Weber, Jeffrey S ^k,o   Wolchok, Jedd D ⁿ   Thompson, John A ^v   more..

^a CHRISTUS St Frances Cabrini Cancer Center   (Egypt)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^e US OncologyVirginia Cancer Specialists   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ Patient Advocate   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^p ONCOLOGY NURSING SOCIETY   (United States)

^q UNIVERSITY OF WASHINGTON   (United States)

^r Oncology Specialists SC   (United States)

^s UNIVERSITY OF OKLAHOMA   (United States)

^t PRINCESS MARGARET HOSPITAL   (Canada)

^u BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^v MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BETAMETHASONE; CLOBETASOL; CORTICOSTEROID; CYCLOSPORINE; DIMETICONE; EMOLLIENT AGENT; FLUDROCORTISONE; HYDROCORTISONE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOGLOBULIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEVOTHYROXINE; METHYLPREDNISOLONE; MINERALOCORTICOID; MYCOPHENOLATE MOFETIL; PETROLATUM; POTASSIUM IODIDE; PREDNISONE; PROPYLTHIOURACIL; RITUXIMAB; SUNSCREEN; TESTOSTERONE; THIAMAZOLE; THYROID HORMONE; TRIAMCINOLONE; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ACQUIRED HEMOPHILIA; ADRENAL INSUFFICIENCY; ANDROGEN THERAPY; ANTIBIOTIC THERAPY; APLASTIC ANEMIA; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTONOMIC NEUROPATHY; BLEPHARITIS; BLOOD TOXICITY; BULLOUS SKIN DISEASE; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; COLITIS; CORTICOSTEROID THERAPY; DERMATITIS; DIABETES MELLITUS; DIAGNOSTIC TEST; DOCTOR PATIENT RELATION; DRUG ERUPTION; DRUG INDUCED DISEASE; ENCEPHALITIS; ENDOCRINE DISEASE; EPISCLERITIS; ESTROGEN THERAPY; EYE TOXICITY; GASTROINTESTINAL TOXICITY; GUILLAIN BARRE SYNDROME; HEALTH DISPARITY; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE FAILURE; HEMOLYTIC UREMIC SYNDROME; HEMOPHILIA; HEPATITIS; HORMONAL THERAPY; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RELATED ADVERSE EVENT; IRITIS; LUNG TOXICITY; LYMPHOCYTOPENIA; MEDICAL SOCIETY; META ANALYSIS; MULTIPLE CHRONIC CONDITIONS; MYASTHENIA GRAVIS; MYELITIS; MYOCARDITIS; MYOSITIS; NEPHRITIS; NEPHROTOXICITY; NEUROTOXICITY; PERICARDITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEVERE CUTANEOUS ADVERSE REACTION; SKIN TOXICITY; SYMPTOMATIC NEPHRITIS; SYSTEMATIC REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOPICAL TREATMENT; UVEITIS; VASCULITIS; VENOUS THROMBOEMBOLISM; ADULT; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; NEOPLASM;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85048283183     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.77.6385     Document Type: Article

References (168)

1. Dine J, Gordon R, Shames Y, et al: Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs 4: 127-135, 2017
2. Postow M, Wolchok J: Toxicities Associated With Checkpoint Inhibitor Immunotherapy. In: UpToDate, Atkins MB (Ed), UpToDate, Waltham, MA, 2017.
3. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
4. Weber JS, Yang JC, Atkins MB, et al: Toxicities of immunotherapy for the practitioner. J Clin Oncol 33: 2092-2099, 2015
5. Weber JS, Kähler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697, 2012
6. Villadolid J, Amin A: Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res 4: 560-575, 2015
7. Eggermont AM, Chiarion-Sileni V, Grob JJ: Correction to Lancet Oncol 2015; 16: 522-30.
8. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 16: e262, 2015
9. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010
10. Freeman-Keller M, Kim Y, Cronin H, et al: Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22: 886-894, 2016
11. Hua C, Boussemart L, Mateus C, et al: Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152: 45-51, 2016
12. Weber JS, O'Day S, Urba W, et al: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26: 5950-5956, 2008
13. Teulings HE, Limpens J, Jansen SN, et al: Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. J Clin Oncol 33: 773-781, 2015
14. Hsieh AHC, Ferman M, Brown MP, et al: Vedolizumab: A novel treatment for ipilimumab-induced colitis. BMJ Case Reports, 2016. http://casereports.bmj.com/content/2016/bcr-2016-216641
15. Bergqvist V, Hertervig E, Gedeon P, et al: Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 66: 581-592, 2017
16. Diana P, Mankongppaisarnrung C, Charabaty A: Vedolizumab: A novel approach to the treatment of immune checkpoint inhibitors-induced enterocolitis, World Congress of Gastroenterology ACG 2017 Annual Scientific Meeting, Orlando, FL, October 16, 2017
17. Gupta A, De Felice KM, Loftus EV Jr., et al: Systematic review: Colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42: 406-417, 2015
18. Cabanillas G: Immune related adverse events and their treatment in melanoma patients receiving ipilimumab. J Clin Oncol 35, 2017 (suppl; abstr e14598)
19. Kumar V, Chaudhary N, Garg M, et al: Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8: 49, 2017
20. Abdel-Rahman O, Elhalawani H, Fouad M: Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Immunotherapy 7, 2015
21. Kwon ED, Drake CG, Scher HI, et al: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, doubleblind, phase 3 trial. Lancet Oncol 15: 700-712, 2014
22. Marthey L, Mateus C, Mussini C, et al: Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn's Colitis 10: 395-401, 2016
23. Cramer P, Bresalier RS: Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 19: 3, 2017
24. Chen JH, Pezhouh MK, Lauwers GY, et al: Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 41: 643-654, 2017
25. Berman D, Parker SM, Chasalow SD, et al: Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. J Clin Oncol 26: 3022, 2008 (suppl 15)
26. Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical. endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenteral Hepatol 14: 836-842, 2016
27. Jain A, Lipson EJ, Sharfman WH, et al: Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol 23: 2023-2028, 2017
28. Weber J: Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58: 823-830, 2009
29. Ziemer M, Koukoulioti E, Simon JC, et al: Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 66: 657-659, 2017
30. Tripathi A, Kaymakcalan MD, LeBoeuf NR, et al: Programmed cell death-1 pathway inhibitors in genitourinary malignancies: Specific side-effects and their management. Curr Opin Urol 26: 548-555, 2016
31. Pollack MH, Betof A, Dearden H, et al: Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29: 250-255, 2017
32. Menzies AM, Johnson DB, Ramanujam S, et al: Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28: 368-376, 2017
33. Weber JS, Kudchadkar RR, Gibney GT, et al: Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. J Clin Oncol 31: 9011, 2013
34. Kyi C, Hellmann MD, Wolchok JD, et al: Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2: 19, 2014
35. Haanen JBAG, Carbonnel F, Robert C, et al: Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: iv119-iv142, 2017 (suppl 4)
36. Champiat S, Lambotte O, Barreau E, et al: Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 27: 559-574, 2016
37. Spain L, Diem S, Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44: 51-60, 2016
38. Postow MA. Managing Immune Checkpoint-Blocking Antibody Side Effects. Am Soc Clin Oncol Educ Book 76-83, 2015
39. Naidoo J, Wang X, Woo KM, et al: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. 35: 709-717, 2017
40. Nishino M, Giobbie-Hurder A, Hatabu H, et al: Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol 2: 1607-1616, 2016
41. Chuzi S, Tavora F, Cruz M, et al: Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 9: 207-213, 2017
42. Barjaktarevic IZ, Qadir N, Suri A, et al: Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143: 858-861, 2013
43. Tirumani SH, Ramaiya NH, Keraliya A, et al: Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3: 1185-1192, 2015
44. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11: 155-164, 2010
45. Margolin K, Ernstoff MS, Hamid O, et al: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13: 459-465, 2012
46. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372: 2006-2017, 2015
47. Santini FC, Rizvi H, Wilkins O, et al: Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol 35: 2017 (suppl 9012)
48. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33: 2004-2012, 2015
49. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018-2028, 2015
50. Nagata S, Ueda N, Yoshida Y, et al: Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 16: 340-344, 2010
51. Hwang WL, Niemierko A, Hwang KL, et al: Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy. JAMA Oncol. Published online September 27, 2017. doi:10.1001/jamaoncol.2017.3808
52. Hassel JC, Heinzerling L, Aberle J, et al: Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 57: 36-49, 2017
53. Friedman CF, Proverbs-Singh TA, Postow MA: Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2: 1346-1353, 2016
54. O'Kane GM, Labbé C, Doherty MK, et al: Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist 22: 70-80, 2017
55. Bashey A, Medina B, Corringham S, et al: CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113: 1581-1588, 2009
56. Montaudié H, Pradelli J, Passeron T, et al: Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 176: 1060-1063, 2017
57. Danlos FX, Pagès C, Baroudjian B, et al: Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 149: e133-e136, 2016
58. Reuss JE, Kunk PR, Stowman AM, et al: Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: A case report & review of the literature. J Immunother Cancer 4: 94, 2016
59. Blansfield JA, Beck KE, Tran K, et al: Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28: 593-598, 2005
60. Faje AT, Sullivan R, Lawrence D, et al: Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99: 4078-4085, 2014
61. Ryder M, Callahan M, Postow MA, et al: Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution. Endocr Relat Cancer 21: 371-381, 2014
62. Min L, Hodi FS, Giobbie-Hurder A, et al: Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21: 749-755, 2015
63. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol, 2017. Published online September 28, 2017. doi:10.1001/jamaoncol.2017.3064
64. Bornstein SR, Allolio B, Arlt W, et al: Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101: 364-389, 2016
65. Fleseriu M, Hashim IA, Karavitaki N, et al: Hormonal replacement in hypopituitarism in adults: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101: 3888-3921, 2016
66. Persani L, Bonomi M, Radin R, et al: Diagnostic and therapeutic challenges of acquired thyrotropic deficiency. Ann Endocrinol (Paris) 73: 138-140, 2012
67. Fliers E, Bianco AC, Langouche L, et al: Thyroid function in critically ill patients. Lancet Diabetes Endocrinol 3: 816-825, 2015
68. Suarez-Almazor ME, Kim ST, Abdel-Wahab N, et al: Review: Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 69: 687-699, 2017
69. Cappelli L, Gutierrez AK, Shah AA, et al: Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic literature review. Arthritis Care Res 69: 1751-1763, 2016
70. Calabrese L, Velcheti V: Checkpoint immunotherapy: Good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis 76: 1-3, 2016
71. Cappelli LC, Gutierrez AK, Baer AN, et al: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76: 43-50, 2017
72. Cappelli LC, Naidoo J, Bingham CO III, et al: Inflammatory arthritis due to immune checkpoint inhibitors: Challenges in diagnosis and treatment. Immunotherapy 9: 5-8, 2017
73. Kim ST, Tayar J, Trinh VA, et al: Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series. Ann Rheum Dis 76: 2061-2064, 2017
74. Belkhir R, Burel SL, Dunogeant L, et al: Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76: 1747-1750, 2017
75. Shah M, Taylor J, Abdel-Wahab N, et al: Myositis as a complication of checkpoint blockade at a comprehensive cancer center. Presented at Arthritis College of Rheumatology/ARHP Annual Meeting, San Diego, CA, November 3-8, 2017
76. Johnson DB, Balko JM, Compton ML, Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375: 1749-1755, 2016
77. Läubli H, Balmelli C, Bossard M, et al: Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3: 11, 2015
78. Abdel-Wahab N, Shah M, Suarez-Almazor ME: Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One 11: e0160221, 2016
79. Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al: Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med 168: 121-130, 2017
80. Sznol M, Ferrucci PF, Hogg D, et al: Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35: 3815-3822, 2017
81. Wanchoo R, Karam S, Uppal NN, et al: Adverse renal effects of immune checkpoint inhibitors: A narrative review. Am J Nephrol 45: 160-169, 2017
82. Cortazar FB, Marrone KA, Troxell ML, et al: Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638-647, 2016
83. Lipson EJ, Bagnasco SM, Moore J Jr., et al: Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 374: 896-898, 2016
84. Alhamad T, Venkatachalam K, Linette GP, et al: Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant 16: 1332-1333, 2016
85. Spain L, Higgins R, Gopalakrishnan K, et al: Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol 27: 1135-1137, 2016
86. Boils CL, Aljadir DN, Cantafio AW: Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant 16: 2496-2497, 2016
87. Barnett R, Barta VS, Jhaveri KD: Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med 376: 191-192, 2017
88. Suzuki S, Ishikawa N, Konoeda F, et al: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017
89. Cuzzubbo S, Javeri F, Tissier M, et al: Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer 73: 1-8, 2017
90. Kao JC, Liao B, Markovic SN, et al: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017
91. Spain L, Walls G, Julve M, et al: Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Ann Oncol 28: 377-385, 2017
92. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 16: 522-530, 2015
93. Williams TJ, Benavides DR, Patrice KA, et al: Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73: 928-933, 2016
94. Feng S, Coward J, McCaffrey E, et al: Pembrolizumab-induced encephalopathy: A review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol 12: 1626-1635, 2017
95. George JN: How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116: 4060-4069, 2010
96. Joly BS, Coppo P, Veyradier A: Thrombotic thrombocytopenic purpura. Blood 129: 2836-2846, 2017
97. Sayani FA, Abrams CS: How I treat refractory thrombotic thrombocytopenic purpura. Blood 125: 3860-3867, 2015
98. Neunert C, Lim W, Crowther M, et al: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117: 4190-4207, 2011
99. Collins PW, Percy CL: Advances in the understanding of acquired haemophilia A: Implications for clinical practice. Br J Haematol 148: 183-194, 2010
100. Sharma P, Callahan MK, Bono P, et al: Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, openlabel, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17: 1590-1598, 2016
101. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015
102. Inadomi K, Kumagai H, Arita S, et al: Bicytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report. Medicine (Baltimore) 95: e4283, 2016
103. Nair R, Gheith S, Nair SG: Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med 374: 1096-1097, 2016
104. Cooling LL, Sherbeck J, Mowers JC, et al: Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: A new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation. Immunohematology 33: 15-21, 2017
105. Shiuan E, Beckermann KE, Ozgun A, et al: Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 5: 8, 2017
106. Delyon J, Mateus C, Lambert T: Hemophilia A induced by ipilimumab. N Engl J Med 365: 1747-1748, 2011
107. Lozier J: More on hemophilia A induced by ipilimumab. N Engl J Med 366: 280-281, 2012
108. Merryman RW, Armand P: Immune checkpoint blockade and hematopoietic stem cell transplant. Curr Hematol Malig Rep 12: 44-50, 2017
109. Kwon HJ CT, Coté TR, Cuffe MS, et al: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138: 807-811, 2003
110. Kearon C, Akl EA, Ornelas J, et al: Antith-rombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149: 315-352, 2016
111. Lyman GH, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31: 2189-2204, 2013
112. Jain V, Bahia J, Mohebtash M, et al: Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med 19: 36, 2017
113. Wang DY, Okoye GD, Neilan TG, et al: Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 19: 21, 2017
114. Tay RY, Blackley E, McLean C, et al: Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117: 921-924, 2017
115. Heinzerling L, Ott PA, Hodi FS, et al: Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4: 50, 2016
116. Yun S, Vincelette ND, Mansour I, et al: Late onset ipilimumab-induced pericarditis and pericardial effusion: A rare but life threatening complication. Case Rep Oncol Med 2015: 794842, 2015
117. Tomita Y, Sueta D, Kakiuchi Y, et al: Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Ann Oncol 28: 2393-2895, 2017
118. Arangalage D, Delyon J, Lermuzeaux M, et al: Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167: 683-684, 2017
119. Behling J, Kaes J, Münzel T, et al: New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for meta-static melanoma. Melanoma Res 27: 155-158, 2017
120. Reddy N, Moudgil R, Lopez-Mattei JC, et al: Progressive and reversible conduction disease with checkpoint inhibitors. Can J Cardiol 33: 1335.e13-1335.e15, 2017
121. Roth ME, Muluneh B, Jensen BC, et al: Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther 23: e1925-e1928, 2016
122. Pasadhika S, Rosenbaum JT: Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 8: 67-81, 2014
123. Doctor P, Sultan A, Syed S, et al: Infliximab for the treatment of refractory scleritis. Br J Ophthalmol 94: 579-583, 2008
124. Voskens C, Cavallaro A, Erdmann M, et al: Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30: e356-e357, 2012
125. Attia P, Phan GQ, Maker AV, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 23: 6043-6053, 2005
126. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532, 2015
127. Ribas A, Hamid O, Daud A, et al: Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315: 1600-1609, 2016
128. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030, 2014
129. Patnaik A, Socinski MA, Gubens MA, et al: Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol 33: 8011-8011, 2015
130. Johnson DB, Sullivan RJ, Ott PA: Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune conditions. JAMA Oncol 2: 234-240, 2016
131. Abdel-Wahab N, Shah M, Suarez-Almazor M: Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune diseases: A systematic review of case reports. World Congress of Gastroenterology ACG2017 Annual Scientific Meeting Washington, DC, November 11-16, 2016
132. Abdel-Rahman O, Fouad M: Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Ther Adv Respir Dis 10: 183-193, 2016
133. Zhang S, Liang F, Zhu J, et al: Risk of pneumonitis associated with programmed cell death 1 inhibitors in cancer patients: A meta-analysis. Mol Cancer Ther 16: 1588-1595, 2017
134. Minkis K, Garden BC, Wu S, et al: The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-Analysis. J Am Acad Dermatol 69: e121-e128, 2013
135. Khunger M, Rakshit S, Pasupuleti V, et al: Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest 152: 271-281, 2017
136. Chaput N, Lepage P, Coutzac C, et al: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28: 1368-1379, 2017
137. Dubin K, Callahan MK, Ren B, et al: Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7: 10391, 2016
138. Michot JM, Bigenwald C, Champiat S, et al: Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 54: 139-148, 2016
139. Feng Y, Roy A, Masson E, et al: Exposure-response relationships of the efficacy and safety of ipilimumabinpatients with advanced melanoma. Clin Cancer Res 19: 3977-3986, 2013
140. Davies M, Duffield EA: Safety of checkpoint inhibitors for cancer treatment: Strategies for patient monitoring and management of immune-mediated adverse events. ImmunoTargets Ther 6: 51-71, 2017
141. Jin C, Zhang X, Zhao K, et al: The efficacy and safety of nivolumab in the treatment of advanced melanoma: A meta-analysis of clinical trials. Onco Targets Ther 9: 1571-1578, 2016
142. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
143. Hodi FS, Chesney J, Pavlick AC, et al: Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipili-mumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol 17: 1558-1568, 2016
144. Weber JS, Postow M, Lao CD, et al: Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21: 1230-1240, 2016
145. Zhang S, Liang F, Li W, et al: Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis. Eur J Cancer 83: 71-79, 2017
146. Schadendorf D, Wolchok JD, Hodi FS, et al: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J Clin Oncol 35: 3807-3814, 2017
147. Carlino MS, Sandhu S: Safety and efficacy implications of discontinuing combination ipilimumab and nivolumab in advanced melanoma. J Clin Oncol 35: 3792-3793, 2017
148. Fay AP, Moreira RB, Nunes Filho PRS, et al: The management of immune-related adverse events associated with immune checkpoint blockade. Expert Rev Qual Life Cancer Care 1: 89-97, 2016
149. Weber JS, Hodi FS, Wolchok JD, et al: Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 35: 785-792, 2017
150. Bayer V, Amaya B, Baniewicz D, et al: Cancer immunotherapy: An evidence-based overview and implications for practice. Clin J Oncol Nurs 21: 13-21, 2017
151. Rubin KM: Understanding immune checkpoint inhibitors for effective patient care. Clin J Oncol Nurs 19: 709-717, 2015
152. Vazquez A: Hypophysitis: Nursing management of immune-related adverse events. Clin J Oncol Nurs 21: 154-156, 2017
153. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol 35: 3618-3632, 2017
154. Jones K, Siegel B, Mead H, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, Commonwealth Fund, 2008
155. National Cancer Institute: SEER Cancer Statistics Review, 1975-2013 http://seer.cancer.gov/csr/1975-2013/
156. American Cancer Society: Cancer Facts & Figures for African Americans 2016-2018. Atlanta, GA, American Cancer Society, 2016
157. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2014 Incidence and Mortality Web-based Report, 2017. http://www.cdc.gov/uscs
158. Ramalingam SS: Lung cancer: Disparities and implications for immunotherapy. 8th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Atlanta, GA, November 13-16, 2015
159. Cogdill AP, Andrews MC, Wargo JA: Hallmarks of response to immune checkpoint blockade. Br J Cancer 117: 1-7, 2017
160. O'Connor J, Seidl-Rathkopf K, Torres AZ, et al: Racial disparities in the use of programmed death-1 checkpoint inhibitors. J Clin Oncol 35: 3068, 2017
161. Ibrahim RA, Berman DM, DePril V, et al Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. J Clin Oncol 29(15: supp 1), 2011
162. Rosenberg JE, Hoffman-Censits J, Powles T, et al Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387: 1909-1920, 2016
163. Nanda R, Chow LQM, Dees EC, et al Pembrolizumab in patients with advanced triple-negative breast cancer: Phase 1b KEYNOTE-012 study. J Clin Oncol 34: 2460-2467, 2016
164. Naidoo J, Page DB, Li BT, et al: Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26: 2375-91, 2015.
165. Ann Oncol 27: 1362, 2016
166. Go RS, Winters JL, Kay NE: How I treat autoimmune hemolytic anemia. Blood, 129: 2971-2979, 2017
167. United States prescribing information for avelumab available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118 (Accessed on Feb 7, 2018).
168. United States prescribing information for ate-zolizumab available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee (Accessed on Feb 7, 2018).